MariTide vs Retatrutide
How MariTide and Retatrutide compare — what each is, how strong the human evidence is for each, doses reported in research, the key risks, and 2026 US legal status. No universal winner.
MariTide and Retatrutide come up together when people are weighing similar options. Here's the honest side-by-side: what each is, how strong the human evidence is for each, the doses reported in research, the risks, and where each stands with the FDA as of 2026. There's no universal winner — scroll to the by-goal picks for which one fits which goal.
MariTide vs Retatrutide, point by point
Every dimension side by side — the honest differences, not a scoreboard.
| Dimension | MariTide | Retatrutide |
|---|---|---|
| What it is | Long-acting GLP-1 receptor agonist and GIP receptor antagonist peptide-antibody conjugate | Synthetic triple-agonist peptide (one molecule that switches on the GIP, GLP-1, and glucagon receptors) |
| Class / category | Incretin / metabolic | Incretin / metabolic |
| Evidence tier | Human RCT · Helped | Human RCT · Helped |
| Studied / approved for | Chronic weight management; Obesity with type 2 diabetes | Obesity / weight loss; Type 2 diabetes; MASLD (fatty liver disease); Obesity-related cardiovascular & kidney outcomes; Knee osteoarthritis pain in people with obesity or overweight; Obstructive sleep apnea in people with obesity |
| US regulatory status (2026) | investigational (as of Jul 2026) | investigational (as of Jul 2026) |
| Doses reported in research | No established study doses | No established study doses |
| Registered trials (ClinicalTrials.gov) | No data | 33 |
| Banned in sport (WADA) | Yes — on the WADA prohibited list | Yes — on the WADA prohibited list |
| Key risks | Gastrointestinal adverse events were common in Phase 2, especially nausea, vomiting, diarrhea, and constipation. Lower starting doses and gradual dose escalation reduced these problems, but the candidate has no approved label and no post-marketing safety record. Phase 3 is testing whether a slower start can keep the weight-loss effect while making treatment easier to tolerate. | Retatrutide has more human safety data than most compounds on this site, because it has reported phase 3 trials — but it is still investigational and its long-term profile is being filled in during ongoing phase 3 studies. The most common side effects are gastrointestinal (nausea, vomiting, diarrhea, constipation), dose-related and usually heaviest early on. Like other incretin drugs, it carries a rodent thyroid C-cell tumor signal whose human relevance is unsettled, and it raises heart rate in a dose-dependent way. |
- Evidence tier: A tier reflects how human the evidence is, not a promise the compound works.
Which one fits which goal?
There's no universal winner here — the honest answer depends on what you're after. These picks are framed by goal, and each says why.
Which one fits your goal
These two overlap enough that the honest call comes down to your specific goal and how much human evidence you want before trying something. Compare the differences in the table above — there's no universal winner here.
References
- 1.Jastreboff et al., 2025 — Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity (PMID 40549887)
- 2.Véniant et al., 2024 — GIPR antagonist conjugated to GLP-1 analogues (PMC10896721)
- 3.NCT05669599 — Phase 2 dose-ranging study of AMG 133
- 4.NCT06858839 — MARITIME-1 Phase 3 study
- 5.NCT06858878 — MARITIME-2 Phase 3 study
- 6.FDA UNII record — maridebart cafraglutide (Z24U3U73HN)